GlassScriptPhysician profile
Emily K Recker
NPI 1083266902
$1,750.21
in general payments reported to CMS, 2019-2025
23 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $46.36 · 2022: $263 · 2023: $463 · 2024: $486 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,440.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $304.23 | 2022-2025 | Wainua, Brilinta, Farxiga |
| Boston Scientific Corporation | $221.86 | 2021-2023 | Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $208.26 | 2021-2025 | Lifevest |
| Abiomed | $177.42 | 2024-2025 | Impella |
| Amgen INC. | $135.13 | 2023-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $116.87 | 2022-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $104.81 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.23 | 2022-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $63.55 | 2023-2024 | Camzyos, Eliquis |
| Lexicon Pharmaceuticals, INC. | $55.66 | 2023-2024 | Inpefa |
| Chiesi USA, INC. | $52.63 | 2024-2025 | Kengreal, Cleviprex |
| Heartflow, INC. | $28.99 | 2025 | |
| Incyte Corporation | $21.93 | 2025 | Monjuvi, Zynyz |
| Pfizer INC. | $19.90 | 2025 | |
| Stemline Therapeutics INC. | $19.44 | 2025 | Orserdu |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $19.19 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $17.67 | 2025 | Fruzaqla |
| Abbott Laboratories | $17.61 | 2025 | Cardiomems |
| Janssen Biotech, INC. | $17.58 | 2025 | Talvey, Darzalex |
| Abbvie INC. | $17.54 | 2025 | |
| Teleflex LLC | $17.08 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.10 | 2025 | |
| Terumo Medical Corporation | $14.53 | 2023 | Navicross |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Recker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.